

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**Food and Drug Administration**

[Docket No. FDA-2017-P-0840]

**Determination That OVRETTE (Norgestrel) Tablet, 0.075 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness**
**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) has determined that OVRETTE (norgestrel) tablet, 0.075 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for norgestrel tablet, 0.075 mg, if all other legal and regulatory requirements are met.

**FOR FURTHER INFORMATION CONTACT:** Daniel Gottlieb, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6217, Silver Spring, MD 20993-0002, 301-796-6650.

**SUPPLEMENTARY INFORMATION:** In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to FDA’s approval of an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

OVRETTE (norgestrel) tablet, 0.075 mg, is the subject of NDA 017031, held by HRA Pharma and initially approved on October 23, 1973. OVRETTE is indicated for the prevention of pregnancy in women.

OVRETTE (norgestrel) tablet, 0.075 mg, was discontinued from U.S. distribution on June 7, 2005, and is currently listed in the “Discontinued Drug Product List” section of the Orange Book.

The Weinberg Group submitted a citizen petition dated February 8, 2017 (Docket No. FDA-2017-P-0840), under 21 CFR 10.30, requesting that the Agency determine whether OVRETTE (norgestrel) tablet, 0.075 mg, was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that OVRETTE (norgestrel) tablet, 0.075 mg, was not withdrawn from sale for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that OVRETTE (norgestrel) tablet, 0.075 mg, was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of OVRETTE (norgestrel) tablet, 0.075 mg, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list OVRETTE (norgestrel) tablet, 0.075 mg, in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to this drug product may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that

labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Dated: October 17, 2017.

**Leslie Kux,**
*Associate Commissioner for Policy.*

[FR Doc. 2017-23125 Filed 10-24-17; 8:45 am]

**BILLING CODE 4164-01-P**
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**Food and Drug Administration**

[Docket No. FDA-2011-N-0656]

**Animal Drug User Fee Act; Recommendations; Request for Comments; Extension of Comment Period**
**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability; request for comments; extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA or the Agency) is announcing the availability of the Animal Drug User Fee Act (ADUFA) reauthorization draft recommendations and extending the comment period to allow interested persons 30 days to submit comments on these draft recommendations.

**DATES:** FDA is extending the comment period on the ADUFA reauthorization and draft recommendations. Submit either electronic or written comments on the draft recommendations by November 24, 2017.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before November 24, 2017. The <https://www.regulations.gov> electronic filing system will accept comments until midnight Eastern Time at the end November 24, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to